Ono and Galapagos subsidiary BioFocus sign target discovery agreement in the field of autoimmune disease

13-Jan-2011 - United Kingdom

Ono Pharmaceutical Co., Ltd.  and BioFocus  announced that they have signed a collaboration agreement, focused on discovering novel targets in the field of autoimmune disease.  Under the agreement, BioFocus will receive research funding and success payments based on the progress of the collaboration.  BioFocus will utilize its unique SilenceSelect® target discovery platform to deliver validated targets for Ono’s immunology programs.  Ono aims to find modulators for these targets and generate novel and innovative drug candidates.

“We are delighted to enter into this target discovery collaboration with Ono,” said Dr Chris Newton, SVP Galapagos Services and Managing Director BioFocus. “This agreement again demonstrates our unique position in the target discovery arena to produce valuable additions to our clients’ early discovery pipeline”.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances